A Phase 1, Placebo-Controlled, Double-Blind, Randomized, Single and Multiple Ascending-Dose Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
Part 1 : To evaluate the safety of single-dose KK3910 in healthy volunteers. Part 2 : To evaluate the safety of multiple-dose KK3910 in patients with essential hypertension.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: t
View:
• Voluntary consent to participate in this study must be given (in writing)
• Japanese or non-Asian healthy men 18 to \< 55 years at the time of informed consent ( Japanese healthy men 65 to \< 80 years for the elderly cohort)
• BMI is within the specified range at screening
• Voluntary consent to participate in this study must be given (in writing)
• Japanese patients with essential hypertension, aged 18 to \<65 years at the time of informed consent
• BMI is within the specified range at screening
Locations
Other Locations
Japan
Kitasato University Kitasato Institute Hospital
RECRUITING
Minato-ku
Contact Information
Primary
Kyowa Kirin Co., Ltd.
clinical.info.jp@kyowakirin.com
+81-3-5205-7200
Time Frame
Start Date: 2025-04-03
Estimated Completion Date: 2027-03
Participants
Target number of participants: 144
Treatments
Placebo_comparator: Placebo
Experimental: KK3910
Related Therapeutic Areas
Sponsors
Leads: Kyowa Kirin Co., Ltd.